Trusted Press Release Distribution   Plans | Login    

Briefing Search
Keyword:
Category:

       

    
Author Details
Phillip Fleck

Bookmark and Share
Amazing Biotech Stock: CURE Pharmaceutical (OTCQB: CURR) Is A Developer Of Patented Drug Delivery
$10 Million Financing Completed to Strongly Expand Global Marketing and Drive Revenue Returns.

BriefingWire.com, 11/21/2020 - FDA-Registered, NSF® and cGMP-Certified Manufacturing Facility.

Patented Techniques Improve Efficacy, Safety, and Patient Experience.

$10 Million Financing Deal Completed to Expand Marketing Worldwide.

Wholly Owned Subsidiary SeraLabs® Introduces Nutri-Strips™, a new

Oral Thin Film Strip Technology for Sleep Aid and Immunity Applications.

CURE Pharmaceutical (OTCQB: CURR) is a fully integrated and progressive drug delivery company. The CURR team has extensive experience formulating and manufacturing OTC products, pharmaceuticals, and veterinary medications placing quality and service as its top priorities, earning the trust and respect of customers worldwide.

As a vertically integrated company, CURR operates a 25,000 square foot, FDA-registered, NSF® and cGMP-certified manufacturing facility enabling it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURR currently has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.

CURE Pharmaceutical Closes $10 Million Financing

On November 2nd CURR announced it had received the first tranche of $4 million in a committed financing of $10 million, after original issue discounts, through the issuance of convertible notes. Axiom Capital Management, Inc. acted as the sole placement agent in the transaction. CURR may repay the obligations of the notes in cash only, or the notes may be converted upon election of the investor at a fixed price of $1.32 per share subject to certain adjustments.

Wholly Owned Subsidiary SeraLabs® Introduces Nutri-Strips™, a Revolutionary Oral Thin Film Strip Technology

On October 29th CURR announced its wholly owned subsidiary Sera Labs was launching the Nutri-Strips brand with a multi-channel advertising and marketing strategy beginning initially with “Sleep A.S.A.P.™,” which offers a fast-acting, drug-free solution to America’s sleep problem.

The company’s recent acquisition by of Sera Labs was fueled largely to help commercialize Nutri-Strip. CURR management expects to see a steep sales trajectory as of a result of its extensive marketing, brand penetration and education campaigns. Now, more than ever consumers are hyper focused on their health and pocketbook and Nutri-Strips solves this problem by offering maximum potency of essential vitamins and supplements while not breaking the bank.

The CURR Nutri-Strip line is non-addictive, has no side effects and is created by top formulation scientists. Each strip is hermetically sealed in airtight, grab-and-go packaging to eliminate chemical and structural breakdown and provide superior potency. Most recently, Nutri-Strip was touted at a prominent virtual industry trade show for buyers in retail as the most innovative line in the supplement category seen in years.

For more information on CURE Pharmaceutical (OTCQB: CURR) visit: www.curepharmaceutical.com/ and seralabshealth.com/

###

 
 
FAQs | Contact Us | Terms & Conditions | Privacy Policy
© 2020 Proserve Technology, Inc.